84O Neoadjuvant nivolumab (N)+ platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
Background The phase III CheckMate 816 study demonstrated statistically significant and
clinically meaningful improvements in event-free survival (EFS) and pathologic complete
response (pCR) with neoadjuvant N+ C vs C in patients (pts) with resectable NSCLC. Here,
we report 3-y efficacy, safety, and exploratory biomarker analyses from CheckMate 816.
Methods Adults with stage IB (tumors≥ 4 cm)–IIIA (per AJCC 7th ed) resectable NSCLC,
ECOG PS≤ 1, and no known EGFR/ALK alterations were randomized to N 360 mg+ C Q3W …
clinically meaningful improvements in event-free survival (EFS) and pathologic complete
response (pCR) with neoadjuvant N+ C vs C in patients (pts) with resectable NSCLC. Here,
we report 3-y efficacy, safety, and exploratory biomarker analyses from CheckMate 816.
Methods Adults with stage IB (tumors≥ 4 cm)–IIIA (per AJCC 7th ed) resectable NSCLC,
ECOG PS≤ 1, and no known EGFR/ALK alterations were randomized to N 360 mg+ C Q3W …
以上显示的是最相近的搜索结果。 查看全部搜索结果